Curis to Present New Data from TakeAim Leukemia Study

Curis, Inc., based in Lexington, Massachusetts, has made significant progress in the field of biotechnology with its lead product, emavusertib (CA-4948). Emavusertib is an orally available, small molecule IRAK4 inhibitor that is undergoing various clinical trials. The company recently announced that it will present updated data from the TakeAim Leukemia study on Tuesday, May 14, 2024, at 4:00 p.m. ET. Following the presentation, the company’s management will host a conference call at 4:30 p.m. ET to discuss the findings.

To join the live conference call, participants from the United States can dial 800-836-8184, while those from other locations can call 646-357-8785. Additionally, the conference call will be accessible via the Curis website in the 'Investors' section. A replay will be available on the website shortly after the conference call concludes.

Curis is dedicated to the development of emavusertib, which is currently being evaluated in several clinical studies. One of these is the Phase 1/2 TakeAim Lymphoma study, which examines the drug in combination with the BTK inhibitor ibrutinib for patients with relapsed or refractory primary central nervous system lymphoma (PCNSL). Another pivotal study is the Phase 1/2 TakeAim Leukemia trial that tests emavusertib as a monotherapy for patients with relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (hrMDS). Both of these conditions have been granted Orphan Drug Designation by the U.S. Food and Drug Administration.

Furthermore, emavusertib is being investigated as a frontline combination therapy alongside azacitidine and venetoclax in patients with AML. Curis holds an exclusive license to emavusertib through a collaboration with Aurigene, established in 2015. Besides emavusertib, Curis has also licensed its rights to Erivedge® to Genentech, a Roche Group member. Genentech is commercializing Erivedge® for treating advanced basal cell carcinoma.

This announcement underscores Curis's commitment to advancing treatments for challenging cancers and highlights the potential of emavusertib in various therapeutic settings. The company's upcoming presentation and subsequent conference call are anticipated to provide critical insights into the effectiveness and future direction of their research.